PRURIGO NODULARIS
Clinical trials for PRURIGO NODULARIS explained in plain language.
Never miss a new study
Get alerted when new PRURIGO NODULARIS trials appear
Sign up with your email to follow new studies for PRURIGO NODULARIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug shows promise for relieving unbearable itch in rare skin disease
Symptom relief OngoingThis study tests an experimental drug called barzolvolimab in 140 adults with prurigo nodularis, a condition that causes intense itching and hard bumps on the skin. The main goal is to see if the drug can significantly reduce itch severity over 12 weeks compared to a placebo. Par…
Matched conditions: PRURIGO NODULARIS
Phase: PHASE2 • Sponsor: Celldex Therapeutics • Aim: Symptom relief
Last updated May 17, 2026 05:25 UTC
-
New study tracks Real-World dupilumab use for itchy skin condition
Symptom relief OngoingThis study follows 100 adults with prurigo nodularis whose doctors have already decided to treat them with dupilumab. Researchers will observe how the drug is used in real life, including dosing changes and reasons for stopping. The goal is to understand long-term effectiveness a…
Matched conditions: PRURIGO NODULARIS
Sponsor: Sanofi • Aim: Symptom relief
Last updated May 17, 2026 05:07 UTC
-
New pill may stop the maddening itch of prurigo nodularis
Symptom relief OngoingThis study tests an experimental drug called povorcitinib in 346 adults with prurigo nodularis, a condition causing intense itching and hard bumps on the skin. Participants receive either the drug or a placebo for 24 weeks. The main goal is to see if the drug significantly reduce…
Matched conditions: PRURIGO NODULARIS
Phase: PHASE3 • Sponsor: Incyte Corporation • Aim: Symptom relief
Last updated May 17, 2026 05:05 UTC
-
New drug shows promise for severe itch in Long-Term trial
Symptom relief OngoingThis study tests the long-term safety of nemolizumab in about 500 adults with prurigo nodularis, a condition causing intense itching and skin bumps. Participants who completed earlier nemolizumab trials will receive the drug for up to 184 weeks. Researchers will track side effect…
Matched conditions: PRURIGO NODULARIS
Phase: PHASE3 • Sponsor: Galderma R&D • Aim: Symptom relief
Last updated May 14, 2026 12:02 UTC
-
New drug offers hope for chronic itch sufferers
Symptom relief OngoingThis study tests a drug called rocatinlimab in adults with prurigo nodularis, a skin condition causing intense itching and bumps. Participants have not gotten enough relief from creams or ointments. The goal is to see if the drug reduces itching and clears skin lesions over 24 we…
Matched conditions: PRURIGO NODULARIS
Phase: PHASE3 • Sponsor: Amgen • Aim: Symptom relief
Last updated May 11, 2026 20:39 UTC